Comment
It is fascinating to read about the "behind-story" on the development of statins. Though, the discussion seems like a bit of marketing for Lipitor when newer potent statins like Crestor are completely missed out even when they are already several years in the market. While bent on discussing carcinogenetic risk as a concern for statins, the author failed to mention the more relevent complications like liver function derangement or myalgia (dose related drawbacks that pushed the development of newer classes of statins like Crestor). As a sidetrack, the relevance of hyper-triglyceridemia and whether statin monotherapy could replace fibrates (was there any historical intention to do so?) is also omitted.
posted by Leo Sham
September 3, 2008
About once a month at Sigma Xi headquarters, we liven up the lunch hour with an American Scientist Pizza Lunch talk. In these informal lectures, scientists describe new research to nonscientists. The series is light on jargon but heavy on solid science. Each Pizza Lunch offers an in-depth look at its subject, whether it's bedbugs or the smart grid. Click below to read about and download these talks -- and to subscribe!
JSTOR, the online academic archive, now contains complete back issues of American Scientist from its inception in 1913 (as Sigma Xi Quarterly) through 2005.
The table of contents for each issue is freely available to all users; those with institutional access can read each complete issue.
View the full collection here.